Date: 2016-09-15
Type of information: Nomination
Compound:
Company: OSE Immunotherapeutics (France)
Therapeutic area: Autoimmune diseases - Cancer - Oncology - Transplantation
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 15, 2016, OSE Immunotherapeutics announced the appointment of Iris Pauporté as Clinical Project Director to reinforce the team’s scientific expertise. OSE immunotherapeutics reinforces its clinical team with the appointment of Iris Pauporté as Clinical Project Director for the clinical development of Tedopi®, an innovative combination of neoepitopes developed in immuno-oncology. Iris will be leading the international registration Phase 3 clinical trial with Tedopi®, an innovative combination of neoepitopes developed in
immuno-oncology in advanced lung cancer (NSCLC). She will also be involved in the preparation of a Phase 2 clinical trial considered in 2017 with Tedopi® combined with a checkpoint inhibitor, and in exploring Tedopi® in other cancer indications.
Iris Pauporté holds a PhD in molecular biology and has more than 20 years’ experience in biomedical and clinical research, both in the pharmaceutical industry and at the French National Cancer Institute. Her expertise in coordinating large-scale scientific programs, coupled with her established relationships with many of the opinion leaders in oncology and immuno-oncology are major assets for the development of OSE Immunotherapeutics’
programs in immuno-oncology. Iris contributed to outstanding research projects and is a coauthor of numerous publications in prestigious scientific journals.
Financial terms:
Latest news:
